Pharma Collaborations
Enabling Precision Medicine in Critical Care
SphingoTec partners with pharmaceutical companies to advance the development of targeted therapies in acute and critical care. Our biomarkers are designed to identify and monitor key disease pathways, supporting the selection of patients most likely to benefit from innovative treatments.
Biomarker-driven patient stratification
Our biomarkers enable precise identification of responders and non-responders, facilitating patient enrichment strategies and maximizing clinical trial efficacy
De-risking drug development
By integrating robust diagnostic markers into clinical studies, pharma partners can improve endpoint accuracy, reduce trial costs, and accelerate regulatory approval.
Supporting precision medicine
SphingoTec’s solutions help bridge the gap between diagnostics and therapeutics, paving the way for personalized approaches in critical care.
Use case:
Our biomarker bio-ADM is used by Adrenomed AG for patient stratification in clinical trials for sepsis therapies, exemplifying the value of diagnostics in supporting drug development and regulatory milestones.
Reach out to us
Neuendorfstr. 15A
16761 Hennigsdorf, Germany
info@sphingotec.com
*Disclaimer
Sphingotest® penKid® and sphingotest® bio-ADM®are offered for research use only. “penKid” and “bio-ADM” represent the analytes Proenkephalin A 119-159 and bioactive Adrenomedullin 1-52, respectively.